Stefan Oliver | Cryogenic Electron Tomography | Best Researcher Award

Published on by Cell Biologist

Dr. Stefan Oliver | Cryogenic Electron Tomography | Best Researcher Award

SLAC National Accelerator Laboratory | United States

Dr. Stefan L. Oliver is a leading virologist and structural biologist whose research focuses on understanding virus–host interactions and the structural organization of viral complexes within infected cells. As Lead Scientist at the SLAC National Accelerator Laboratory, Stanford University, he directs laboratory operations and research programs centered on the tomographic reconstruction and segmentation of macromolecular assemblies in situ, particularly investigating the varicella-zoster virus (VZV) using advanced cryo-focused ion beam/scanning electron microscopy (cryoFIB/SEM) and cryo-electron tomography (cryo-ET). His work integrates cutting-edge imaging technologies with molecular virology to elucidate the ultrastructural mechanisms of viral infection, replication, and pathogenesis. At the Stanford University School of Medicine, Dr. Oliver’s research advances the understanding of viral morphogenesis and host cell remodeling during infection, contributing to the broader field of structural virology. His studies provide critical insights into how viral particles assemble and interact with cellular machinery at the nanoscale level. In addition to his research, Dr. Oliver serves as an Associate Editor for Frontiers in Microbiology – Virology and has guest-edited a special issue of Viruses on “Virus-Induced Syncytia,” highlighting his active role in advancing scholarly communication within the virology research community.

Profiles: Google Scholar | Orcid

Featured Publications:

Oliver, S. L., Chen, M., Engel, L., Hecksel, C. W., Zhou, X., Schmid, M. F., Arvin, A. M., & Chiu, W. (2025). Cryogenic electron tomography redefines herpesvirus capsid assembly intermediates inside the cell nucleus. bioRxiv. https://doi.org/10.1101/2025.06.27.661840

Engel, L., Zaoralova, Z., Dunn, A. R., & Oliver, S. L. (2025). Extracellular filaments revealed by affinity capture cryoelectron tomography of lymphocytes. Nature Communications, 16, 9802. https://doi.org/10.1038/s41467-025-64795-z

Zhou, M., Vollmer, B., Machala, E., Chen, M., Grünewald, K., Arvin, A. M., Chiu, W., & Oliver, S. L. (2023). Targeted mutagenesis of the herpesvirus fusogen central helix captures transition states. Nature Communications, 14(1), 7958. https://doi.org/10.1038/s41467-023-43011-w

Alexander, L. T., Lepore, R., Kryshtafovych, A., et al. (2021). Target highlights in CASP14: Analysis of models by structure providers. Proteins: Structure, Function, and Bioinformatics. https://doi.org/10.1002/prot.26247

Oliver, S. L., Xing, Y., Chen, D. H., Roh, S. H., Pintilie, G. D., Bushnell, D. A., Sommer, M. H., Yang, E., Carfi, A., Chiu, W., & Arvin, A. M. (2021). The N-terminus of varicella-zoster virus glycoprotein B has a functional role in fusion. PLoS Pathogens, 17(3), e1008961. https://doi.org/10.1371/journal.ppat.1008961

Zhou, M., Kamarshi, V., Arvin, A. M., & Oliver, S. L. (2020). Calcineurin phosphatase activity regulates varicella-zoster virus-induced cell-cell fusion. PLoS Pathogens, 16(11), e1009022. https://doi.org/10.1371/journal.ppat.1009022

Oliver, S. L., Xing, Y., Chen, D., Roh, S. H., Pintilie, G. D., Bushnell, D. A., Sommer, M. H., Yang, E., Carfi, A., Chiu, W., & Arvin, A. M. (2020). A glycoprotein B-neutralizing antibody structure at 2.8Å uncovers a critical domain for herpesvirus fusion initiation. Nature Communications, 11(1), 4141. https://doi.org/10.1038/s41467-020-17911-0

Yang, E., Gardner, M. R., Zhou, A. S., Farzan, M., Arvin, A. M., & Oliver, S. L. (2018). HIV-1 inhibitory properties of eCD4-Igmim2 determined using an Env-mediated membrane fusion assay. PLoS ONE, 13(10), e0206365. https://doi.org/10.1371/journal.pone.0206365

Yang, E., Arvin, A. M., & Oliver, S. L. (2017). The glycoprotein B cytoplasmic domain lysine cluster is critical for varicella-zoster virus cell-cell fusion regulation and infection. Journal of Virology, 91(4), e01707-16. https://doi.org/10.1128/JVI.01707-16

Georgios Karras | Protein Folding Chaperones | Best Researcher Award

Published on by Cell Biologist

Assoc. Prof. Dr. Georgios Karras | Protein Folding Chaperones | Best Researcher Award

The University of Texas MD Anderson Cancer Center | United States

Dr. Georgios Karras is a molecular geneticist whose research focuses on understanding cellular stress responses and genome stability mechanisms, with implications for cancer development and therapy. His work explores how cells maintain protein homeostasis and genomic integrity under physiological and pathological stress, integrating molecular genetics, biochemistry, and systems biology approaches. Through his research, Dr. Karras investigates molecular pathways that regulate proteostasis, DNA repair, and chromatin dynamics, aiming to uncover how their dysregulation contributes to tumorigenesis. His studies have advanced understanding of the molecular mechanisms that link protein quality control systems to genome maintenance, providing insights into how stress adaptation influences cancer cell survival and progression. Dr. Karras’s laboratory also develops innovative genetic and biochemical models to study these processes, combining yeast and mammalian systems to identify conserved stress response mechanisms. His research has received recognition through multiple national awards and funding programs, including support from cancer research foundations and the National Cancer Institute. By elucidating the interplay between cellular stress signaling and genome stability, Dr. Karras’s work contributes to the development of novel strategies for targeting stress-related vulnerabilities in cancer cells, offering new perspectives for precision oncology and therapeutic interventions.

Profiles: Scopus | Orcid

Featured Publications:

Gracia, B., Zhang, X. H., Montes, P., Pham, T. C., Huang, M., Chen, J., & Karras, G. I. (2024). HSP90 buffers deleterious genetic variations in BRCA1. bioRxiv [Preprint].

Karras, G. I., Colombo, G., & Kravats, A. N. (2025). Hsp90: Bringing it all together. Cell Stress & Chaperones, 30(1), 69–79.

Condic, N., Amiji, H., Patel, D., Shropshire, W., Lermi, N. O., Sabha, Y., John, B., Hanson, B., & Karras, G. I. (2024). Selection for robust metabolism in domesticated yeasts is driven by adaptation to Hsp90 stress. Science, 385(6707), eadi3048.

Gracia, B., Montes, P., Gutierrez, A. M., Arun, B., & Karras, G. I. (2024). Protein-folding chaperones predict structure-function relationships and cancer risk in BRCA1 mutation carriers. Cell Reports, 43(2), 113803.

Carter, B. Z., Mak, P. Y., Muftuoglu, M., Tao, W., Ke, B., Pei, J., Bedoy, A. D., Ostermann, L. B., Nishida, Y., Isgandarova, S., Sobieski, M., Nguyen, N., Powell, R. T., Martinez-Moczygemba, M., Stephan, C., Basyal, M., Pemmaraju, N., Boettcher, S., Ebert, B. L., … Karras, G. I. (2023). Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells. Blood, 142(12), 1056–1070.

Cesare Orlandi | GPCR signaling pathways | Best Researcher Award

Published on by Cell Biologist

Assoc. Prof. Dr. Cesare Orlandi | GPCR signaling pathways | Best Researcher Award

Assoc. Prof. Dr. Cesare Orlandi, University of Rochester, United States

Dr. Cesare Orlandi is an accomplished Associate Professor of Pharmacology and Physiology at the University of Rochester School of Medicine & Dentistry. With a multidisciplinary background in pharmaceutical biotechnology and molecular genetics, Dr. Orlandi has made significant contributions to GPCR (G protein-coupled receptor) biology, orphan receptor deorphanization, and signal transduction. His work bridges basic molecular pharmacology with translational applications in neuroscience and immunology. He has authored numerous high-impact publications in leading journals like Science, Nature Communications, and Journal of Medicinal Chemistry. His collaborative research with global institutions reflects a strong network and broad scientific reach. Recognized for his excellence in science communication, Dr. Orlandi has received multiple “Best Talk” awards at competitive research symposia. His lab continues to innovate at the frontier of receptor biology, influencing therapeutic strategies in neurobiology and inflammation.

Publication Profile: 

Scopus

Orcid

Strengths for the Award:

  1. High-Impact Publications in Prestigious Journals
    Dr. Orlandi has published in top-tier, peer-reviewed journals, including Science, Nature Communications, PNAS, Journal of Physiology, and Molecular Pharmacology. This reflects the scientific rigor, innovation, and broad relevance of his work.

  2. Research Innovation in GPCR Biology
    His research into orphan G protein-coupled receptors (GPCRs) has led to the development of new experimental assays (e.g., GzESTY) and has provided significant insights into immune and neurological signaling mechanisms. These contributions are not only fundamental but also highly translational, aligning with drug discovery and therapeutic interventions.

  3. Strong Interdisciplinary and Collaborative Profile
    Dr. Orlandi’s collaborations with diverse teams across pharmacology, structural biology, and immunology underscore his interdisciplinary approach. His name appears alongside experts from multiple institutions, showing leadership in team science.

  4. Recognition for Scientific Communication
    His awards for Best Talk at Scripps Research Fest (2016, 2018) and selection for a Gordon Research Seminar oral presentation affirm his strength in communicating complex science effectively—an essential trait for broader impact.

  5. Mentorship and Leadership
    As an Associate Professor at the University of Rochester, Dr. Orlandi plays an active role in training the next generation of biomedical researchers, contributing to capacity building in academia.

Areas for Improvement:

  1. Limited Mention of Funding Sources or Grant Leadership
    While his publication record is excellent, there’s no clear listing of major research grants or principal investigator (PI) roles, which are critical markers for research independence and sustainability.

  2. More Visible Clinical or Translational Output
    While his work is biologically impactful, the clinical translation or patenting aspect could be made more visible to demonstrate tangible applications beyond academic impact.

  3. Leadership in International Consortia or Editorial Boards
    Additional involvement in editorial boards, scientific committees, or research policy advisory roles would further bolster his profile as a leader in his field.

Education:

Dr. Orlandi earned his Ph.D. in Molecular Genetics from the University of Brescia, Italy (2005–2009), where he conducted foundational research into genetic signaling mechanisms. Prior to that, he completed a Master of Science in Pharmaceutical Biotechnology at the University of Milan (1998–2004), equipping him with a robust interdisciplinary foundation in drug development, pharmacodynamics, and molecular biology. His academic path reflects a strong European biomedical training system, with emphasis on translational pharmacology and therapeutic innovation. The combination of pharmaceutical science and genetic research uniquely positions Dr. Orlandi to explore receptor biology with a precision medicine lens. His training was further strengthened by postdoctoral research in elite institutions, where he deepened his specialization in orphan GPCR signaling. This education forms the backbone of his research productivity and ability to mentor the next generation of molecular pharmacologists.

Experience:

Dr. Cesare Orlandi currently serves as Associate Professor in the Department of Pharmacology and Physiology at the University of Rochester. He has established himself as a leading voice in the GPCR research community, especially in understanding orphan receptors and their roles in neuronal and immune systems. Prior to this, he held postdoctoral and research positions where he collaborated with global leaders in receptor signaling and neurobiology. His lab combines pharmacological, molecular, and computational approaches to tackle fundamental questions about receptor activity, bias, and downstream signaling. With over a decade of hands-on research experience and extensive publication output, Dr. Orlandi has trained graduate students and postdocs who have progressed into independent academic and industry positions. His multidisciplinary experience spans receptor pharmacology, molecular neuroscience, and drug discovery, making him a cornerstone in collaborative biomedical research projects at the University of Rochester and beyond.

Awards and Honors:

Dr. Orlandi’s scientific excellence has been recognized with several prestigious honors. Notably, he received the Best Talk Award at the Scripps Research Fest in both 2016 and 2018, underscoring his ability to clearly and impactfully communicate complex scientific findings. In 2016, his work was also selected for an oral presentation at the highly competitive Gordon Research Seminar on Phosphorylation and G-Protein Mediated Signaling, affirming the novelty and relevance of his contributions to the receptor signaling field. These awards highlight not only the depth of his scientific insights but also his excellence in mentorship, collaboration, and thought leadership. They place him among a select group of researchers with both technical and communicative brilliance, a critical trait for academic and translational science leadership. These recognitions, combined with high-impact publications, position Dr. Orlandi as a deserving candidate for the Best Researcher Award.

Research Focus:

Dr. Orlandi’s research revolves around orphan G protein-coupled receptors (GPCRs)—a class of proteins that are vital drug targets but remain largely unexplored. His lab develops novel assays (like GzESTY) for GPCR deorphanization, helping decode their physiological roles in the brain and immune system. He also explores signaling bias, investigating how different ligands induce distinct signaling cascades through the same receptor. His recent work uncovered pivotal roles for orphan GPCRs in macrophage immune function and neuronal communication, highlighting their therapeutic potential. Collaborating across pharmacology, neuroscience, and structural biology, he integrates in vitro, in vivo, and computational methods. His lab has also contributed to understanding how GPCRs interact with psychoactive cannabinoids and prostaglandins, which has implications for pain, inflammation, and psychiatric disorders. His research is highly translational, aiming to inform next-generation drug discovery in neuropharmacology and immunomodulation.

Publications Top Notes: 

  1. 🧬 Distinct Interactions of Cannabinol and Its Cytochrome P450-Generated Metabolites with Receptors and Sensory Neurons – Journal of Medicinal Chemistry, 2025

  2. 🧪 Pancreatic Exocrine Signaling and Function Require Gαq Activation – The Journal of Physiology, 2025

  3. 🧫 GzESTY: An Optimized Cell-Based Assay for GPCR Deorphanization – Nature Communications, 2025

  4. 🧉 Orphan GPCR GPRC5B Controls Macrophage Function via Prostaglandin E2 Signaling – Nature Communications, 2025

  5. 🧠 Gα Protein Signaling Bias at the 5-HT1A Receptor – Molecular Pharmacology, 2023

  6. 🧠 Spatial Profile of Orphan GPCR GPRC5B Expression in Mouse Brain – Frontiers in Neuroscience, 2022

  7. 🔍 In Vitro Profiling of Orphan GPCR Constitutive Activity – British Journal of Pharmacology, 2021

  8. 🧩 Cell-Adhesion Molecules Regulate Cone Photoreceptor Synaptic Wiring – PNAS, 2020

  9. 🎮 NF1-cAMP Signaling Links Striatal Neurons to Reward and Motor Control – PLOS Biology, 2019

  10. 🚫 Genetic Behavioral Screen Identifies an Orphan Anti-Opioid System – Science, 2019

Conclusion:

Dr. Cesare Orlandi stands out as an exceptional researcher whose work has advanced the frontiers of molecular pharmacology, especially in the complex field of orphan GPCRs. His innovative methodologies, strong publication track record, and interdisciplinary collaborations make a compelling case for recognition through the Best Researcher Award. While there is room to further highlight his grant leadership and translational reach, his scientific output and leadership are already at a level that merits this award.

Tao Liang | Cell Death Pathway | Best Researcher Award

Published on by Cell Biologist

Mr. Tao Liang | Cell Death Pathway | Best Researcher Award

Mr. Tao Liang, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, China

Dr. Tao Liang is an accomplished medicinal chemist with deep expertise in small molecule drug design, synthesis, and pharmacological evaluation. Originating from Dancheng County, Henan Province, and currently residing in Wuhu City, Anhui Province, Dr. Liang is an Assistant Researcher at The Second Affiliated Hospital of Wannan Medical College. He earned his Doctor of Medicine from Shandong University, a leading institution under China’s “Double First-Class” initiative. With over 7 first-author SCI publications and multiple national invention patents, his research significantly contributes to targeted cancer therapies, especially involving HDAC6-selective inhibitors and Bax agonists. He has successfully led key projects funded by the Anhui Provincial Government and participated in prestigious National Natural Science Foundation of China projects. Known for both scientific depth and innovation, Dr. Liang has been recognized with national-level scholarships and university-wide honors for outstanding research achievements and academic excellence.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. High-Impact Publications

    • Authored 7 first-author SCI papers, including publications in top-tier journals like Acta Pharm Sin B (IF 14.907) and J Med Chem (IF 8.039).

    • Published extensively on HDAC6 isoform-selective inhibitors and apoptosis-targeting small molecules, a niche and cutting-edge domain in anticancer drug research.

  2. Research Leadership & Innovation

    • Serves as Principal Investigator for two key provincial research projects focusing on selective cancer therapies.

    • Demonstrated innovation in designing dual-target inhibitors (MMP/HDAC) and novel Bax agonists.

  3. National-Level Collaborations

    • Participated in major National Natural Science Foundation of China projects (5 total), totaling over RMB 2 million in funding.

    • Engaged with multidisciplinary teams and key opinion leaders, including renowned researchers such as Prof. Hao Fang and Prof. Xuben Hou.

  4. Academic Recognition

    • Winner of prestigious honors such as the National Scholarship, Outstanding Doctoral Graduate, and guest speaker at elite academic forums.

    • Recipient of 15+ national and university-level awards, including innovation prizes and scholarships.

  5. Patent Contributions

    • Holds 4 national invention patents, reflecting translational potential and real-world application of his research outputs.

🔧 Areas for Improvement:

  1. International Visibility & Collaboration

    • Current research impact is primarily within domestic circles (China). Engaging in cc, postdoctoral exchanges, or publishing with international co-authors would elevate recognition.

  2. Clinical Translation Pipeline

    • Despite strong preclinical development, there is no direct evidence of transition to clinical trials or industrial commercialization. Partnering with biotech/pharma could increase translational outcomes.

  3. Leadership Beyond Research

    • As an early-career researcher, administrative leadership (e.g., lab director, national committee memberships) may still be developing. Building a research group or mentoring PhD students would strengthen this.

  4. Interdisciplinary Expansion

    • Expertise is strong in medicinal chemistry, but cross-disciplinary projects involving AI/drug discovery, systems biology, or clinical oncology could broaden the impact.

🎓 Education:

Dr. Tao Liang received his Bachelor of Science in Pharmacy from Shandong University (2013.9–2017.6), one of China’s elite institutions under the National “985 Project” and “Double First-Class” initiative. Continuing at the same university, he pursued a Master’s and Ph.D. in Medicinal Chemistry, earning a Doctor of Medicine degree in 2022. Shandong University, renowned for its Ministry of Education Class A-rated disciplines, provided Dr. Liang with a rigorous scientific environment and access to state-of-the-art research facilities. During his academic training, he developed a strong foundation in chemical biology, natural product synthesis, and drug development. His educational journey has been marked by consistent excellence, earning him accolades like National Scholarships and Outstanding Graduate awards. His academic credentials and extensive research during his Ph.D. have positioned him as a leading young researcher in the field of medicinal chemistry in China.

💼 Work Experience:

Since August 2022, Dr. Tao Liang has been serving as an Assistant Researcher at The Second Affiliated Hospital of Wannan Medical College. His research focuses on the structural design, chemical synthesis, and pharmacological activity evaluation of small molecule drugs, particularly targeting HDAC isoforms and apoptotic regulators like Bax. He currently leads two key projects: one on HDAC6-selective inhibitors and another on Bax agonists for cervical cancer therapy, funded by the Anhui Provincial Higher Education and Health Commission respectively. Previously, he participated in several high-impact national research projects, including two funded by the National Natural Science Foundation of China, focusing on anti-cancer drug discovery. His roles have involved both independent project leadership and critical collaboration within multidisciplinary teams. Dr. Liang’s work experience showcases his capabilities in translational medicinal chemistry research and positions him as a promising talent in pharmaceutical innovation.

🏆 Awards and Honors:

Dr. Tao Liang has received more than a dozen honors for his outstanding academic and research contributions. These include the prestigious National Scholarship (2021), Outstanding Doctoral Graduate of Shandong University (2022), and multiple first-class scholarships throughout his postgraduate studies. He was a special guest speaker at prominent forums like the “Haiyou Doctoral Forum” and “Lao Xu Talks about High Strategies.” His undergraduate years were equally distinguished, earning the first prize in the ‘Challenge Cup’ and honors like “Outstanding Graduate” and “Excellent Communist Youth League Member”. His early career was also decorated with international recognitions such as the First Prize for Innovation Results at the World University Students’ Pharmaceutical Garden Forum. These awards highlight both his academic brilliance and commitment to scientific advancement, affirming his eligibility and strength as a nominee for the Best Researcher Award.

🔬 Research Focus:

Dr. Tao Liang’s research centers on the design, synthesis, and biological evaluation of small molecule inhibitors with a primary focus on histone deacetylase 6 (HDAC6) isoform-selective inhibitors and Bax agonists for cancer therapy. His work integrates computational modeling, medicinal chemistry, and pharmacodynamics to create targeted therapies aimed at epigenetic modulation and apoptosis induction in cancer cells. He has actively contributed to national-level projects exploring dual-target inhibitors (MMP/HDAC) and small molecule interventions for Mcl-1 and striatal enriched tyrosine phosphatase (STEP) targets. Dr. Liang is particularly recognized for his innovation in optimizing chemical scaffolds for selective inhibition and minimizing off-target effects. Through collaborative and independent research, he aims to address challenges in chemotherapeutic resistance and toxicity. His scientific pursuits align with current global trends in precision oncology, making significant strides in targeted therapy development and laying a foundation for future clinical translation.

📚 Publications Top Notes:

  1. 📘 Design, synthesis and evaluation of structural optimization derived HDAC6 isoform-selective inhibitor – Bioorganic Chemistry, 2025

  2. 📗 Targeting histone deacetylases for cancer therapy: Trends and challenges – Acta Pharmaceutica Sinica B, 2023

  3. 📙 Potential applications of BPFP1 in Bcl-2 protein quantification, carcinoma cell visualization, cell sorting and early cancer diagnosis – European Journal of Medicinal Chemistry, 2021

  4. 📕 Design, synthesis and biological evaluation of 3,4-disubstituted-imidazolidine-2,5-dione derivatives as HDAC6 selective inhibitors – European Journal of Medicinal Chemistry, 2021

  5. 📘 Recent Development of Novel HDAC6 Isoform-selective Inhibitors – Current Medicinal Chemistry, 2021

  6. 📗 HDAC–Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells – Journal of Medicinal Chemistry, 2020

  7. 📙 Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors – ACS Medicinal Chemistry Letters, 2019

  8. 📕 Synthesis and Antiproliferative Activity of Thiadiazole Peptidomimetic Derivatives – Chinese Journal of Organic Chemistry, 2016

🧾 Conclusion:

Dr. Tao Liang is highly suitable for the Best Researcher Award, especially in the early- to mid-career researcher category. His extensive publication record, innovative medicinal chemistry work, leadership in funded projects, and impressive academic recognitions make him an exemplary candidate.

Mohammad Rezaul Islam Shishir | Cell Structure Analysis | Best Researcher Award

Published on by Cell Biologist

Dr. Mohammad Rezaul Islam Shishir | Cell Structure Analysis | Best Researcher Award

Dr. Mohammad Rezaul Islam Shishir , Jiangsu University , China

Dr. Mohammad Rezaul Islam Shishir is an accomplished researcher in the field of food science and engineering, specializing in food bioactive compounds, micro and nano-encapsulation, and functional food formulation. With a strong academic background and extensive research experience, he has contributed significantly to developing advanced delivery systems for bioactive compounds. His research focuses on enhancing the stability, bioavailability, and controlled-release properties of natural products. Currently serving as a Postdoctoral Researcher at Jiangsu University, China, Dr. Shishir has received prestigious awards, including the Jiangsu Provincial Excellent Postdoctoral Award. His groundbreaking research in nanoliposomal delivery and food-based smart carriers has led to numerous high-impact publications in renowned journals. His dedication to innovation and scientific advancement makes him a prominent figure in food science, contributing to both academia and the food industry.

Publication Profile:

Scopus

Strengths for the Award:

✅ Extensive Research Experience – Dr. Shishir has a strong background in food science, particularly in nano-encapsulation and functional food development.
✅ High-Impact Publications – His research has been published in top-tier journals such as Food Chemistry, Food Hydrocolloids, and Comprehensive Reviews in Food Science and Food Safety, with impact factors reaching up to 15.1.
✅ Innovative Research – His work on nanoliposome-based drug delivery and cold plasma-assisted food processing has significantly contributed to food science advancements.
✅ Recognized Excellence – Awarded the Jiangsu Provincial Excellent Postdoctoral Award (2023ZB876), highlighting his contributions to scientific innovation.

Areas for Improvement:

🔹 Interdisciplinary Collaboration – Expanding research collaborations across medical and pharmaceutical fields could further enhance the practical applications of his work.
🔹 Patent & Commercialization – Translating research findings into patents and commercial food products would increase real-world impact.
🔹 Leadership in Grant Projects – Leading large-scale international grants and mentorship programs could elevate his recognition in the global research community.

Education 🎓

Dr. Mohammad Rezaul Islam Shishir has an extensive educational background in food engineering and food science. He completed his PhD in Food Science (2016–2020) from Zhejiang University, China, where he focused on improving the stability and functionality of nanoliposome-based delivery systems. His MSc in Food Engineering (2013–2016) was earned from Universiti Putra Malaysia, Malaysia, where he specialized in advanced food processing techniques. Dr. Shishir began his academic journey with a BSc in Food and Process Engineering (2007–2011) from Hajee Mohammad Danesh Science & Technology University, Bangladesh. His studies have equipped him with expertise in food bioactive compounds, nano-encapsulation, and smart delivery systems for functional foods. His academic training, combined with hands-on research, has positioned him at the forefront of food innovation, working towards the development of efficient and sustainable food processing technologies.

Experience 👨‍🔬

Dr. Mohammad Rezaul Islam Shishir is currently a Postdoctoral Researcher (June 2023 – Present) at the School of Food and Biological Engineering, Jiangsu University, China. His research focuses on developing nanoliposome-embedded double-network composite hydrogel beads for gastrointestinal delivery of quercetin. During his PhD at Zhejiang University, he contributed to two major projects: nanoliposomal delivery systems and cold plasma-assisted drying of shiitake mushrooms. His expertise extends to food bioactive compounds, micro and nano-encapsulation, and functional food formulations. Throughout his career, Dr. Shishir has developed novel nanofiber solosomes, complex coacervates, emulsions, and lipo-beads for improved bioavailability and stability of bioactive compounds. His work has led to significant advancements in the controlled-release delivery of natural compounds in food products, making his research highly valuable for both academia and industry.

Awards & Honors🏆

Dr. Mohammad Rezaul Islam Shishir has been recognized for his outstanding contributions to food science research. He was awarded the prestigious Jiangsu Provincial Excellent Postdoctoral Award (2023ZB876) in 2023, offered by the Jiangsu Provincial Party Committee, Department of Human Resources and Social Security, and Department of Finance, China. This award, valued at 300,000 CNY (~$41,600), is a testament to his remarkable research achievements in functional food formulation and nanotechnology-based delivery systems. His innovative approaches to enhancing bioactive compound stability and bioavailability have been widely acknowledged in the scientific community. His dedication to advancing food science, coupled with his contributions to high-impact research, make him a strong candidate for prestigious research awards.

Research Focus 🔬

Dr. Mohammad Rezaul Islam Shishir’s research focuses on food bioactive compounds, micro and nano-encapsulation, and functional food development. He specializes in fabricating nanoliposomes, nanofibers, microbeads, emulsions, and lipo-beads to improve the stability, bioavailability, and controlled-release of natural compounds. His work also includes the synthesis of functional biopolymers for surface coating and cross-linking to develop smart delivery systems for bioactive ingredients. His projects have explored the use of lactoferrin, chia seed mucilage, and pectin-chitosan nanoliposomes for improved nutrient absorption and targeted delivery in the human body. By integrating cutting-edge techniques such as stimuli-responsive carriers and cold plasma technology, Dr. Shishir’s research aims to revolutionize the food and nutraceutical industries by ensuring better stability, enhanced functionality, and improved consumer health benefits.

Publications Top Notes 📚

1️⃣ Lactoferrin-chia seed mucilage complex coacervates for intestinal delivery of quercetin and fortification of set yogurt – Food Chemistry (2024)
2️⃣ Micro and nano-encapsulated natural products in yogurt: An emerging trend to achieve multifunctional benefits in product quality and human health – Food Hydrocolloids (2024)
3️⃣ Seed mucilage carrier systems for food and nutraceuticals: fabrication, formulation efficiency, recent advancements, challenges, and perspectives – Critical Reviews in Food Science and Nutrition (2023)
4️⃣ Advances in smart delivery of food bioactive compounds using stimuli-responsive carriers – Comprehensive Reviews in Food Science and Food Safety (2021)
5️⃣ Development and evaluation of a novel nanofibersolosome for enhancing the stability, in vitro bioaccessibility, and colonic delivery of cyanidin-3-O-glucoside – Food Research International (2021)
6️⃣ Improving the physicochemical stability and functionality of nanoliposome using green polymer for the delivery of pelargonidin-3-O-glucoside – Food Chemistry (2021)
7️⃣ Colonic delivery of pelargonidin-3-O-glucoside using pectin-chitosan-nanoliposome: Transport mechanism and bioactivity retention – International Journal of Biological Macromolecules (2020)
8️⃣ Pectin-chitosan conjugated nanoliposome as a promising delivery system for neohesperidin – Food Hydrocolloids (2019)
9️⃣ Liposomal delivery of natural products: A promising approach in health research – Trends in Food Science & Technology (2019)
🔟 Cold plasma pretreatment – A novel approach to improve the hot air-drying characteristics and nutritional attributes of shiitake mushroom – Drying Technology (2019)

Conclusion

Dr. Mohammad Rezaul Islam Shishir’s expertise in food bioactive compounds, nano-encapsulation, and functional foods positions him as a highly deserving candidate for the Best Researcher Award. His publications in high-impact journals, combined with his innovative research on food delivery systems and bioactive compound stability, make him an outstanding researcher in his field. Strengthening industry collaborations and expanding his influence in applied food science would further solidify his legacy.

Sona Jain | Protein structural analysis | Best Researcher Award

Published on by Cell Biologist

Assist. Prof. Dr. Sona Jain | Protein structural analysis | Best Researcher Award

Assist. Prof. Dr. Sona Jain , Federal University of Sergipe , Brazil

Dr. Sona Arun Jain is a distinguished professor and researcher at the Federal University of Sergipe, Brazil, with extensive expertise in microbial drug resistance, genetic engineering, and biotechnological applications. She has made significant contributions to the fields of molecular biology, genetics, and natural product discovery. With over two decades of academic and research experience, Dr. Jain has conducted pioneering work on the cloning and functional analysis of genes in Fusarium oxysporum and other microbial organisms. She has held various prominent academic positions across Brazil, Japan, Canada, and the USA, and supervised numerous students at different academic levels. Her research interests focus on developing novel antimicrobial, biopesticide, and probiotic compounds, as well as exploring alternative methods to combat microbial resistance. Her extensive list of publications includes over 70 journal articles and 46 abstracts, highlighting her profound impact in the field.

Publication Profile:

Google Scholar

Strengths for the Award:

  1. Extensive Academic and Research Experience:
    • Dr. Jain has held significant academic positions, currently serving as a professor and researcher at the Federal University of Sergipe, Brazil, and having extensive prior experience in various universities and research institutions.
    • This includes working as a postdoctoral fellow in prominent research centers, such as the Brazilian Agricultural Research Corporation (Embrapa), and the University of Waterloo, Canada, and the University of Illinois, USA.
  2. Wide Range of Research Interests:
    • Dr. Jain’s research spans several critical and impactful fields including microbial drug resistance, natural product discovery (antimicrobials, biopesticides, probiotics), and fungal genetics, which are highly relevant in addressing global health challenges.
    • Specific focus on microbial drug resistance is crucial in the face of rising antibiotic resistance.
  3. Research Leadership and Student Supervision:
    • Dr. Jain has supervised several doctoral students (5), master’s students (12), and undergraduate research mentorship programs (12), demonstrating an exceptional track record in academic leadership and mentoring.
    • Currently, Dr. Jain is supervising a postdoctoral fellow, 2 doctoral students, and 2 master’s students, highlighting ongoing contributions to the next generation of scientists.
  4. Strong Publication Record:
    • Dr. Jain has contributed to 70 articles in refereed journals and 46 abstracts in congress proceedings, showcasing a strong and continuous output in high-impact scientific publications.
    • Publications in top-tier journals, such as Biomolecules, Critical Reviews in Microbiology, and Journal of Applied Oral Science, reinforce the quality and impact of the research.
  5. International Collaboration:
    • Participation in various international research projects with collaborators from multiple countries (Japan, Canada, USA, Brazil) demonstrates a collaborative mindset and the ability to work across borders.
    • Collaborative studies on microbial biopesticides, leishmaniasis, and antimicrobial resistance are all highly relevant.
  6. Innovative Research in Drug Resistance and Treatment:
    • Dr. Jain has focused on developing novel solutions for drug-resistant pathogens, such as Bacillus thuringiensis, nisin variants, and leishmaniasis treatment, indicating a strong commitment to improving public health through scientific research.
    • Contributions in drug delivery systems, biosensors, and antimicrobial peptides (e.g., nisin) reflect the ability to innovate in biomedical applications.
  7. Research Funding and Recognition:
    • Dr. Jain has been funded by various prestigious research organizations, including the Brazilian Coordination for the Improvement of Higher Education Personnel (CAPES), the Brazilian Agricultural Research Corporation (Embrapa), and the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT).
    • This recognition and support underline the credibility and importance of Dr. Jain’s research contributions.

Areas for Improvement:

  1. Broader Public Engagement:
    • While Dr. Jain’s scientific publications are numerous and impactful, there seems to be limited focus on outreach to the general public, policymakers, or non-scientific stakeholders. Engaging with the broader public through popular science, media, and policy advocacy could help extend the influence of the research.
    • Further dissemination of findings in easily accessible formats (e.g., popular articles, talks, webinars) could contribute to greater societal impact.
  2. Diversity in Research Topics:
    • While Dr. Jain has worked in a variety of topics within microbiology and drug resistance, expanding research into broader areas (e.g., environmental microbiology, climate change, etc.) could diversify the research portfolio.
    • Collaboration with researchers from other scientific disciplines, such as environmental science or computational biology, could bring new dimensions to current research topics.
  3. Increased Involvement in Industry Collaboration:
    • Dr. Jain has an academic background but could increase collaboration with the biotechnology or pharmaceutical industry to translate research findings into real-world applications, particularly in areas such as biopesticides, antimicrobial drug discovery, and vaccines.
  4. Increased Research Impact Measurement:
    • While Dr. Jain has an extensive publication record, there could be a greater emphasis on research impact metrics such as citation indices, patent filings, and real-world application of research. A stronger focus on translating discoveries into tangible products or services may enhance visibility.

Education:

Dr. Sona Arun Jain holds a Ph.D. in Genetic Engineering from Ehime University, Japan (2003), where she conducted groundbreaking research on G protein subunit genes in Fusarium oxysporum under the mentorship of Prof. Dr. Renkichi Takata. This work involved the cloning and functional analysis of these genes through targeted gene disruption. She also earned an M.Ag. (Applied Bioresource Science) from Ehime University (2000), where she focused on isolating nonpathogenic strains of Fusarium oxysporum. Her studies were supported by the Japanese Ministry of Education, Culture, Sports, Science, and Technology (MEXT). Additionally, Dr. Jain completed a Postgraduate Diploma in Public Relations from the University of Mumbai, India (1996), and a B.Sc. in Microbiology from Sophia College, University of Mumbai, India (1995). Her diverse academic background has empowered her to integrate scientific and communicative strategies in her research and teaching.

Experience:

Dr. Sona Arun Jain has an illustrious academic and research career spanning over 20 years, with key positions at top institutions worldwide. Since 2024, she has been a Professor and Researcher at the Federal University of Sergipe, Brazil. Prior to this, she served as a Professor and Researcher at Tiradentes University (2019-2023) and a Visiting Researcher at renowned institutions such as the University of Waterloo, Canada, and the University of Illinois at Urbana-Champaign, USA. Her research experience also includes significant contributions at the Brazilian Agricultural Research Corporation (Embrapa), where she worked on the development of ELISA tests and the identification of cotton diseases. As a visiting researcher and research fellow, Dr. Jain has made notable advancements in molecular biology, antimicrobial research, and biotechnological applications. Throughout her career, she has mentored and supervised numerous doctoral, master’s, and undergraduate students, shaping the next generation of scientists.

Research Focus:

Dr. Sona Arun Jain’s research focuses on microbial drug resistance, natural product discovery, and the development of biotechnological applications in various fields, including health and agriculture. Her work includes the exploration of novel antimicrobials, biopesticides, and probiotics to combat emerging threats from multi-drug resistant microbes. She has also worked extensively on identifying microbial strains with potential medicinal properties and examining their applications in treating diseases like leishmaniasis. Dr. Jain is deeply involved in understanding microbial genetics, particularly through the study of G proteins and their role in pathogenicity. Her work on Bacillus thuringiensis and Cry toxins exemplifies her efforts to find eco-friendly solutions for pest control. Moreover, she focuses on the biosynthesis of bioactive compounds from microorganisms and their use in drug delivery systems. With a strong foundation in molecular biology and microbiology, her research aims to tackle pressing global health and environmental challenges.

Publications Top Notes:

  1. Use of agro-industrial bio-waste for Bacillus thuringiensis growth 🌾🐛
  2. Nisin variants: what makes them different and unique? 🧀🔬
  3. Brazilian essential oils with leishmanicidal activity 🌿💉
  4. Biosensor-integrated drug delivery systems for biomedical applications 🧪💡
  5. Chromatographic profiles of Bacillus sp. from Brazilian Mangroves 🌿🧫
  6. Bacillus thuringiensis: from biopesticides to anticancer agents 🦠💊
  7. Volatile nitrogenous compounds from bacteria: novel bioactive sources 🦠🔬
  8. Antileishmanial compounds from microbial metabolites 🦠💀
  9. Nisin resistance in Gram-positive bacteria 🦠🔒
  10. Biological aspects of entomopathogenic fungus Aschersonia 🍄🦠
  11. Multidrug-resistant bacteria and control methods overview 🦠💉
  12. G protein α subunit disruption in Fusarium oxysporum 🔬🍄

Conclusion:

Dr. Sona Arun Jain stands out as a highly accomplished researcher and educator with a solid track record in microbial drug resistance, antimicrobial discovery, and applied biosciences. Her extensive academic career, impressive publication record, research leadership, and international collaborations position her as an exceptional candidate for the Research for Best Researcher Award.

Her contributions to advancing scientific knowledge, especially in drug resistance, biopesticides, and antimicrobial peptides, make her an invaluable asset to the scientific community. Additionally, her passion for mentoring students and supervising young researchers ensures that her impact will continue to resonate for years to come.

With slight improvements in public engagement, cross-disciplinary research, and industry collaboration, Dr. Jain’s career trajectory could become even more influential in shaping the future of scientific research in her fields of expertise. Therefore, Dr. Jain is strongly recommended for this prestigious award.